Publications

Improving the future of early cancer detection through clinical studies.

Extracellular vesicle-based biomarker assay for the detection of early-stage ovarian cancer

OVARIAN CANCER

2022 American Society of Clinical Oncology (ASCO) Annual Meeting

 

Detection of cancer with improved discrimination compared to current blood tests could be achieved using an approach that assesses extracellular vesicles (EVs). This approach should have high sensitivity (se) because of EVs abundance in blood and high specificity (sp) by assaying EVs with multiple cancer-related protein and glycosylation epitopes (PGEs) co-localized on their surfaces. We are developing a platform technology that detects multiple cancer-related PGEs co-localized on the same EV using immunoaffinity-capture and proximity-ligation qPCR. In this study, we compare the performance of this technology vs plasma CA125 for correctly categorizing early-stage high-grade serous ovarian cancer (HGSOC) vs healthy/benign ovarian tumors (OT).

Preliminary results for a novel single extracellular vesicle assay for early-stage ovarian cancer: The power of co-localized detection of surface biomarkers

OVARIAN CANCER

2022 American Association for Cancer Research (AACR) Annual Meeting

 

These preliminary data suggest that co-localization of surface biomarkers in single EVs may provide an effective means to identify women with early-stage high-grade serous ovarian cancer (HGSOC), including those with normal CA125, while avoiding false positives in women with benign masses and high CA125. Despite the inherent challenges associated with commercial samples, our finding that several combinations detected early-stage HGSOC is promising. Statistically powered studies with curated repository specimens are underway to refine combinations and independently validate our assay for early-stage ovarian cancer detection.

Preliminary results for a novel single extracellular vesicle assay for early lung cancer: The power of co-localized detection of surface biomarkers

LUNG CANCER

2022 American Association for Cancer Research (AACR) Annual Meeting

These preliminary data highlight the potential of detecting biomarkers co-localized on the surface of single EVs as an effective tool for early-stage lung cancer detection, and the benefit of using 3 biomarkers simultaneously. Despite inherent challenges associated with commercial samples, our finding that detection of co-localized EV surface biomarkers distinguished lung adenocarcinoma (LUAD) is promising. Additional studies with lung cancer cohorts beyond LUAD are underway to refine combinations and independently validate our assay for early-stage lung cancer detection.